Given our observation of increased in number and activity of tumour-infiltrating CD8+ and CD4+ T cells in response to combined inhibitor treatment, we reasoned that the T cells might be central to the anti-tumour efficacy of combined inhibitor treatment. Here, CD4 is linked to neoplasm.